Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,964 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (536)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01520558 | CNDO-109-AANK for AML in First Complete Remission (CR1) | unknown | Phase 1 / Phase 2 | 12 | Coronado Biosciences, Inc.INDUSTRY | 1 | Jun 29, 2017 | clinicaltrials |
| NCT00607997 | Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia | completed | Phase 2 | 113 | Sunesis PharmaceuticalsINDUSTRY | 1 | Jun 28, 2017 | clinicaltrials |
| NCT00854945 |
| Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML |
| completed |
| Phase 1 / Phase 2 |
| 36 |
| Traws Pharma, Inc.INDUSTRY |
| 1 |
| Jun 26, 2017 |
| clinicaltrials |
| NCT01167166 | Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) | completed | Phase 1 / Phase 2 | 30 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT00145626 | HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies | completed | Phase 2 | 40 | St. Jude Children's Research HospitalOTHER | 1 | Jun 19, 2017 | clinicaltrials |
| NCT00687323 | Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)(TALL) | completed | Phase 2 | 47 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00003875 | Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia | completed | Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 5, 2017 | clinicaltrials |
| NCT01457885 | Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen(CloBu4) | completed | Phase 2 | 75 | University of Michigan Rogel Cancer CenterOTHER | 2 | Jun 2, 2017 | clinicaltrials |
| NCT00673153 | Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | terminated | Phase 2 | 31 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT00118352 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 2 | May 30, 2017 | clinicaltrials |
| NCT02259348 | Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation | terminated | Phase 2 | 12 | St. Jude Children's Research HospitalOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT01083706 | Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00795769 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | completed | Phase 2 | 49 | Fred Hutchinson Cancer CenterOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT01427881 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT00049504 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | completed | Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT00863434 | Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease | terminated | Phase 2 | 2 | University of WashingtonOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT01435343 | Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia | completed | Phase 1 / Phase 2 | 55 | PETHEMA FoundationOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT02520102 | Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia | withdrawn | Phase 2 | 0 | SanofiINDUSTRY | 0 | Apr 20, 2017 | clinicaltrials |
| NCT02200380 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | terminated | Phase 2 | 36 | Celldex TherapeuticsINDUSTRY | 1 | Apr 7, 2017 | clinicaltrials |
| NCT00636909 | Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders(MINI HEME) | completed | Phase 2 | 25 | Beth Israel Deaconess Medical CenterOTHER | 0 | Apr 6, 2017 | clinicaltrials |
| NCT01465386 | Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission | terminated | Phase 2 | 6 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT01607645 | Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS | terminated | Phase 2 | 7 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT00052520 | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT00880269 | Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 12 | Feb 23, 2017 | clinicaltrials |
| NCT01621477 | T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant | terminated | Phase 2 | 34 | St. Jude Children's Research HospitalOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT01843179 | Sulindac for Patients With AML | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT00052598 | Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 7 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00475150 | Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Feb 15, 2017 | clinicaltrials |
| NCT01567059 | Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 2 | 34 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT03053206 | A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid Leukemia | unknown | Phase 2 | 84 | All India Institute of Medical SciencesOTHER | 0 | Feb 15, 2017 | clinicaltrials |
| NCT00394381 | Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 17 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT00460694 | Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies(alloCIK) | completed | Phase 1 / Phase 2 | 24 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT03045627 | Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients | unknown | Phase 2 | 120 | Shandong UniversityOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT00313586 | Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | completed | Phase 2 | 197 | National Cancer Institute (NCI)NIH | 1 | Feb 2, 2017 | clinicaltrials |
| NCT01520805 | Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome | withdrawn | Phase 2 | 0 | Cornerstone PharmaceuticalsINDUSTRY | 1 | Dec 29, 2016 | clinicaltrials |
| NCT02742727 | CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02944162 | CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT00683046 | T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies | completed | Phase 2 | 204 | University of ChicagoOTHER | 1 | Nov 22, 2016 | clinicaltrials |
| NCT02084563 | Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms | completed | Phase 2 | 455 | Hospital Israelita Albert EinsteinOTHER | 1 | Nov 8, 2016 | clinicaltrials |
| NCT01772953 | Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT | completed | Phase 2 | 40 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Oct 12, 2016 | clinicaltrials |
| NCT01870596 | Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2016 | clinicaltrials |
| NCT02303782 | A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT) | withdrawn | Phase 1 / Phase 2 | 0 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Sep 1, 2016 | clinicaltrials |
| NCT00867672 | Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia(DECIDER) | completed | Phase 2 | 204 | University Hospital FreiburgOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT01758367 | Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT01960387 | Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia(UPCI 13-066) | terminated | Phase 2 | 2 | University of PittsburghOTHER | 1 | Aug 2, 2016 | clinicaltrials |
| NCT02848183 | Optimal Treatment Strategy Based on for Pediatric AML | unknown | Phase 2 | 350 | Samsung Medical CenterOTHER | 1 | Jul 28, 2016 | clinicaltrials |
| NCT01146262 | Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM)(CD lam) | unknown | Phase 1 / Phase 2 | 5 | Nantes University HospitalOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT00079482 | Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML) | completed | Phase 2 | 224 | CephalonINDUSTRY | 13 | Jul 21, 2016 | clinicaltrials |
| NCT00533923 | Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders | completed | Phase 2 | 25 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 18, 2016 | clinicaltrials |
| NCT00778375 | Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | completed | Phase 2 | 122 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 14, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Jun 29, 2017source: clinicaltrials